What more can we learn from DTC ad­ver­tis­ing? FDA's OPDP pro­pos­es new re­search

How do specifics around en­dorse­ments, mech­a­nism of ac­tion and med­ica­tion track­ing in phar­ma­ceu­ti­cal ads im­pact con­sumers? That’s what the FDA’s Of­fice of Pre­scrip­tion Drug Pro­mo­tion (OPDP) wants to find out in three new stud­ies.

OPDP has pro­posed three re­search projects on di­rect-to-con­sumer mar­ket­ing, ac­cord­ing to fed­er­al reg­is­ter no­tices post­ed last week. The stud­ies would join the agency’s ros­ter of 13 on­go­ing projects cov­er­ing a wide range of top­ics, from ac­cel­er­at­ed ap­proval dis­clo­sure to in­ter­pre­ta­tion of drug names.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER